Depressive symptoms and schizophrenic relapses: The effect of four neuroleptic drugs

Mauri, Massimo C.; Bitetto, Antonella; Fabiano, L.R.F. Lucia Rachele; Laini, V.; Steinhilber, C. P C; Fornier, Monica; Rafique, Farouk

doi:10.1016/s0278-5846(98)00090-6

Cited by 20 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may be explained by the less severe psychosis in this sample or that the co‐prescription of antidepressants may denote a group of patients who need smaller doses of first generation antipsychotics. Conversely, the typical antipsychotic may also aggravate depressive symptoms (Mauri et al 1999). Although not assessed in this study, antidepressants have been found useful in a variety of clinical situations including that of comorbid depression, obsessive‐compulsive symptoms or syndromes, negative syndrome, demoralization, and irritability (Silver, 2001; Whitehead et al 2002; Davis et al 2004).…”

Section: Discussionmentioning

confidence: 99%

Adjunctive antidepressant use and its clinical correlates in patients with schizophrenia: an East Asia multicenter comparative prescribing audit

Sim

Fujii

Yang

et al. 2010

Asia-Pacific Psychiatry

View full text Add to dashboard Cite

Aims: Previous pharmacoepidemiological studies have highlighted considerable rates of adjunctive psychotropic medication prescriptions in patients with schizophrenia, including the use of adjunctive antidepressants, but this has not previously been studied in East Asia. This study examined the frequency of adjunctive antidepressant prescriptions in patients with schizophrenia and their clinical correlates in six East Asian countries and territories. Methods: Co-prescription of antidepressants for a sample of 2,136 patients with schizophrenia from six countries and territories (China, Hong Kong, Korea, Japan, Taiwan, Singapore) were evaluated in 2004 using a standardized protocol. Results: Adjunctive antidepressant prescriptions were found in 6.5% (n = 139) of the patients with some intercountry differences. Co-prescription of antidepressants was significantly associated with younger age, shorter duration of index admission, electroconvulsive therapy in the past month, less likelihood of manifesting disorganized speech, and prescription of first generation antipsychotic drugs. Concomitant antidepressant prescription was associated with greater weight and increased number of adverse events including constipation, sedation and sexual dysfunction. On multivariate analysis, it was found that country, younger age and history of electroconvulsive therapy for the past month were significantly associated with adjunctive antidepressant use. Discussion: Adjunctive antidepressant use for schizophrenia in East Asia was associated with a number of demographic, clinical, and treatment variables. The association with greater weight and more adverse events reinforces the notion that prescription of adjunctive psychotropic medication is not without its costs. The challenge for the clinician is to constantly reevaluate the risk benefit ratio in the process of understanding the patient in a holistic context and to optimize the treatment regimes for patients with schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjunctive antidepressant use and its clinical correlates in patients with schizophrenia: an East Asia multicenter comparative prescribing audit

Sim

Fujii

Yang

et al. 2010

Asia-Pacific Psychiatry

View full text Add to dashboard Cite

show abstract

“…The effect of sulpiride on the depressive symptoms could be attributed to its modulation of the liberation of the presynaptic dopamine in the mesocorticolimbic pathway, thus selectively increasing dopamine in areas like the prefrontal cortex. In another comparative study on the effectiveness of four antipsychotics (haloperidol, haloperidol decanoate, fluphenazine decanoate and sulpiride) performed in 114 acutely ill schizophrenia patients, although no significant differences were noted among the different antipsychotics, the sulpiride group showed a tendency to an improvement of the depressive symptoms [70].…”

Section: Antipsychotic Treatmentmentioning

confidence: 96%

Depression in Schizophrenia, Can it be Treated? A Review of the Evidence

Ramı́rez¹,

Arranz²,

Sánchez³

et al. 2006

CPSR

View full text Add to dashboard Cite

Depressive symptoms in schizophrenia patients are not usually the primary therapeutic goal, as the psychiatric evaluation of the schizophrenia is generally based in the assessment of the positive and negative syndrome. However, direct approach of the pure depressive symptoms in schizophrenia is of capital importance from both prognostic and therapeutical perspective. This paper reviews the recently published evidence on the treatment of depressive symptoms in schizophrenia patients, with a special emphasis on the efficacy of different pharmacological families. It also includes studies on the antidepressant effect and pharmacological profile of second-generation antipsychotics. Finally, it addresses the possible confusion between depressive and negative symptoms/extrapyramidal side effects of antipsychotic treatment.

show abstract

“…Clinical studies [29,30] have shown that the typical antispychotic fluphenazine improved depressive symptoms in patients with schizophrenia. The beneficial effect of fluphenazine on depressive symptoms was observed in female schizophrenic patients [30].…”

Section: Treatmentmentioning

confidence: 99%